The Efficacy of Supplemental Saffron in Patients with Age-Related Macular Degeneration

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205219820N1

Enrollment

Registered

2012-09-30

Start date

2011-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration. Degeneration of macula and posterior pole

Interventions

Intervention 1: saffron capsule 15mg, bid, for 6 month. Intervention 2: placebo tablet, bid, for 6 month.

Treatment - Drugs

Placebo

saffron capsule 15mg, bid, for 6 month

placebo tablet, bid, for 6 month

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: visual acuity: 20/40 >? > 20/400; being available; no prior treatment for AMD; definite diagnosis; being between the study range of age. Exclusion criteria: any concurrent ocular disease (e.g. diabetic retinopathy, retinal vascular disease); history of keratoconus; history of glaucoma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ERG. Timepoint: START STUDY.3MONTH.6MONTH. Method of measurement: Amplitude and implicite time.;OCT. Timepoint: at the beginning, month 3 and month 6. Method of measurement: Thickness.	—

Secondary

Measure	Time frame
OCT. Timepoint: 3 month. Method of measurement: thickness.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamreza Sadough

Farabi Eye Hospital

r_sadough@yahoo.com+98 21 5541 6134

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026